Clinical Takeaway
In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to one year. The trial design, including a randomized withdrawal phase, allows for meaningful assessment of both sustained benefit and dependence on continued treatment. Results from this rigorous multicenter study will inform clinical decision-making for patients who have not responded adequately to conventional pharmacologic options.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by providing rigorous evidence on cannabis extract efficacy for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited effectiveness and carry known risks. The double-blind design with 820 participants and 6-month follow-up enables clinicians to make evidence-based decisions about cannabis derivatives as a potential alternative to opioids and other conventional analgesics for CLBP management. If efficacy is demonstrated, these findings could inform clinical guidelines and expand the therapeutic armamentarium for patients with inadequate response to existing treatments.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain addresses a genuine clinical need, given the limitations and risks associated with conventional analgesics like opioids and NSAIDs. However, several important considerations warrant cautious interpretation: the abstract is incomplete, preventing full assessment of primary outcome measures, effect sizes, and safety data; “full-spectrum” formulations contain variable cannabinoid and terpene ratios that may not be reproducible across batches or comparable to other cannabis products; and the 12-week active phase followed by open-label extension creates potential bias in longer-term efficacy claims. The heterogeneity of CLBP itself—spanning mechanical, inflammatory, neuropathic, and psychosocial contributors—suggests that a single botanical extract may have differential effectiveness across patient subgroups, a distinction that phase 3 designs sometimes obscure. If this trial demonstrates clinically meaningful pain reduction with acceptable safety, it could offer patients with CLBP who have
| |